Athenex, Lilly ink clinical collaboration for 1st oral formulation of paclitaxel

Athenex said today that it inked a clinical collaboration deal to conduct a phase Ib study for its oral form of paclitaxel, Oraxol, with Eli Lilly‘s (NYSE:LLY) vascular endothelial growth factor (VEGF) receptor 2 antagonist, Cyramza.

Patients with advanced gastric and esophageal cancer will be enrolled in 2017 at sites in the U.S. and Asia, where Athenex will sponsor the trial and Lilly will supply Cyramza. Cyramza is approved in the U.S. for use as a monotherapy or in combination with paclitaxel as treatment for advanced or metastatic stomach cancers.

Get the full story at our sister site, Drug Delivery Business News.

The post Athenex, Lilly ink clinical collaboration for 1st oral formulation of paclitaxel appeared first on MassDevice.

from MassDevice http://ift.tt/2fcEgzN